KR980008019A - Beverage composition for inhibiting gastric mucosal injury - Google Patents
Beverage composition for inhibiting gastric mucosal injury Download PDFInfo
- Publication number
- KR980008019A KR980008019A KR1019960030501A KR19960030501A KR980008019A KR 980008019 A KR980008019 A KR 980008019A KR 1019960030501 A KR1019960030501 A KR 1019960030501A KR 19960030501 A KR19960030501 A KR 19960030501A KR 980008019 A KR980008019 A KR 980008019A
- Authority
- KR
- South Korea
- Prior art keywords
- gastric mucosal
- beverage composition
- rice bran
- defatted soybean
- mixed fermentation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 230000006378 damage Effects 0.000 title claims abstract description 24
- 235000013361 beverage Nutrition 0.000 title claims abstract description 16
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 12
- 230000002496 gastric effect Effects 0.000 title abstract description 25
- 208000027418 Wounds and injury Diseases 0.000 title abstract description 11
- 208000014674 injury Diseases 0.000 title abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 36
- 235000007164 Oryza sativa Nutrition 0.000 claims abstract description 20
- 235000009566 rice Nutrition 0.000 claims abstract description 20
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 19
- 238000000855 fermentation Methods 0.000 claims abstract description 19
- 230000004151 fermentation Effects 0.000 claims abstract description 19
- 244000068988 Glycine max Species 0.000 claims abstract description 18
- 239000007788 liquid Substances 0.000 claims abstract description 7
- 240000007594 Oryza sativa Species 0.000 claims abstract 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 210000001156 gastric mucosa Anatomy 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- 239000001116 FEMA 4028 Substances 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 2
- 229960004853 betadex Drugs 0.000 claims description 2
- 229940094952 green tea extract Drugs 0.000 claims description 2
- 235000020688 green tea extract Nutrition 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 235000020710 ginseng extract Nutrition 0.000 claims 1
- 230000035622 drinking Effects 0.000 abstract description 9
- 208000024891 symptom Diseases 0.000 abstract description 3
- 241000209094 Oryza Species 0.000 description 15
- 239000003814 drug Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 206010061164 Gastric mucosal lesion Diseases 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 229940000406 drug candidate Drugs 0.000 description 4
- 239000003777 experimental drug Substances 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 102100021022 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000008881 mucosal defense Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
- A23L2/382—Other non-alcoholic beverages fermented
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/104—Fermentation of farinaceous cereal or cereal material; Addition of enzymes or microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Non-Alcoholic Beverages (AREA)
Abstract
본 발명은 위점막 손상 억제용 음료조성물에 관한 것이다. 더욱 구체적으로, 본 발명은 미강과 탈지대두의 혼합발효액을 함유하여 알코올 섭취후에 나타나는 위점막 손상을 억제하는 음료조성물에 관한 것이다. 본 발명의 조성물에서 주성분으로 사용되는 미강과 탈지대두의 혼합발효액은 음주전에 투여함으로써 알코올에 의해 급성적으로 야기되는 위점막 손상을 효과적으로 억제하여 기존의 알코올취 및 구취 제거 효과와 함께 알코올에 의한 제증상을 억제 또는 경감시키는데 유효하다.The present invention relates to a beverage composition for inhibiting gastric mucosal injury. More specifically, the present invention relates to a beverage composition containing a mixed fermentation liquid of rice bran and defatted soybean to inhibit gastric mucosal damage after alcohol consumption. The mixed fermentation broth of rice bran and defatted soybean, which is used as a main component in the composition of the present invention, effectively inhibits gastric mucosal damage caused by alcohol by administering it before drinking, It is effective in inhibiting or alleviating symptoms.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is a trivial issue, I did not include the contents of the text.
에탄올의 독성에 대해서는 이미 널리 알려져 있음에도 불구하고 현대생활에 있어서 음주의 불가피한 역할은 부인할 수 없다. 일찍이 19세기 초에 뷰몽 (Beaumont)이 에탄올이 인체의 위점막에 발적을 동반한 병리학적 변화를 일으킨다고 보고한 이래 이에 대하여 많은 연구가 이루어져 왔다.Although the toxicity of ethanol is already well known, the inevitable role of drinking in modern life can not be denied. Earlier in the early nineteenth century, Beaumont had been studying ethanol since it reported that it causes pathological changes in the gastric mucosa of the human body with redness.
과도한 음주는 인체의 여러 장기에 손상을 초래할 수 있으나 위, 간 및 췌장 등의 소화기관에 손상을 주는 경우가 많고 특히 위점막 손상에 의한 증상을 호소하는 경우를 임상적으로 가장 흔히 경험할 수 있다. 일반적으로 인체에서는 35%이상의 에탄올 농도에서 현저한 점막 및 점막하 출혈, 괴사, 부종 등이 유발되는 것으로 알려져 있다. 에탄올에 의한 위점막손상 기전은 아직 확실하지 않으나 수소이온에 대한 위점막 방어기전의 손상, 가스트린 분비의 촉진, 위점막혈류 장애, 모세혈관의 투과성 변화, 세포보호기전의 필수적인 요인인 산소유리기 제거기전의 저해 등 다양한 병인들이 제시되고 있으며, 특히 최근에는 산소 유리기 제거기전에 많은 관심이 기울여지고 있다. 그러나 이와 같이 알코올이 위점막 손상작용 및 더 나아가서는 위출혈을 야기시키는 작용이 있는 것으로 알려져 있음에도 불구하고, 지금까지 음주후에 복용하는 것으로 알려진 대부분의 약제들은 단순한 소화제이거나 알코올을 분해시켜 제거함으로써 알코올의 혈중농도를 저하시키는 약제, 비타민제, 또는 알코올취를 제거하는 약제 등이 대부분이고, 아직까지 음주후에 복용함으로써 알코올에 의한 급성적인 위점막 손상을 억제하는 효과적인 약제는 개발되지 않았다. 따라서, 음주에 의한 급성적인 위점막 손상을 억제할 수 있는 효과적인 약물의 개발이 요망되고 있다.Excessive drinking can cause damage to various organs of the human body, but it often causes damage to gastrointestinal organs such as stomach, liver and pancreas. Especially, it may be the most common clinical manifestation of symptoms due to gastric mucosal injury. In general, it is known that in the human body, remarkable mucosal and submucosal hemorrhage, necrosis, edema and the like are caused by ethanol concentration of 35% or more. The mechanism of gastric mucosal injury by ethanol is not yet clear, but the inhibition of gastric mucosal defense before hydrogen ion, the promotion of gastrin secretion, gastric mucosal blood flow disorder, capillary permeability change, Recently, a lot of attention has been paid to oxygen free radical scavengers. However, despite the fact that alcohol is known to have an effect of gastric mucosal injury and thus gastrointestinal bleeding, most of the drugs known to be taken after drinking until now are simple extinguishing agents or by decomposing and removing alcohol, Vitamin medicines, or medicines that remove alcohol, and so far, effective medicines have not been developed to suppress acute gastric mucosal damage caused by alcohol by taking it after drinking. Therefore, it is desired to develop an effective drug that can inhibit acute gastric mucosal injury due to drinking.
이러한 욕구에 따라, 최근들어 알코올에 의한 급성적인 독성을 경감시키는 다양한 종류의 음료조성물들이 앞을 다투어 시판되고 있으나 아직까지 이들 약제들이 실제로 알코올에 의한 위점막 손상을 억제하는 약리학적 효능이 있는 지에 대해서는 밝혀지지 않았다. 이에 본 발명자들은 현재 시판되고 있는 음료조성 물중의 하나인 컨디션의 주성분인 미강과 탈지대두의 혼합발효액이 알코올에 의한 위점막 손상에 대한 억제효과가 있는지 여부를 검토하여 보았다.According to this desire, various kinds of beverage compositions that alleviate the acute toxicity by alcohol have recently been on the market, but it is still necessary to know whether these drugs actually have a pharmacological effect of inhibiting gastric mucosal damage by alcohol It was not revealed. Therefore, the present inventors examined whether the mixed fermented liquid of rice bran and defatted soybean, which is one of the presently marketed beverage compositions, as a main ingredient of the condition, has an inhibitory effect on gastric mucosal damage caused by alcohol.
컨디션의 주성분인 미강과 탈지대두의 혼합발효액은 알코올 섭취후의 알코올취 및 구취제거에 효과가 있는 것으로 밝혀져 있으며, 따라서 이에 대하여 이미 특허를 획득한 바 있다(특허 제84493호). 그러나 미강과 탈지대두의 혼합발효액이 음주후의 위점막 손상에 대해서도 억제작용을 가지는지에 대해서는 확인된 바가 없었다.It has been found that the mixed fermented liquid of rice bran and defatted soybeans, which are the main components of the condition, is effective in removing alcohol and bad breath after consumption of alcohol, and thus obtained patent for this (Patent No. 84493). However, it has not been confirmed whether the mixed fermentation liquid of rice bran and defatted soybean has an inhibitory effect on gastric mucosal damage after drinking.
따라서, 본 발명자들은 미강과 탈지대두의 혼합발효액이 에탄올에 의한 위점막 손상을 억제할 수 있는지 여부를 알아보기 위하여 다양한 실험을 수행하였으며, 그 결과 미강과 탈지대두의 혼합발효액이 우수한 위점막 손상 억제작용을 나타냄을 확인하고 본 발명을 완성하게 되었다.Therefore, the present inventors conducted various experiments to determine whether the mixed fermentation broth of rice bran and defatted soy be inhibited gastric mucosal damage by ethanol. As a result, the mixed fermented broth of rice bran and defatted soybean showed excellent gastric mucosal injury inhibition And the present invention has been completed.
따라서, 본 발명은 알코올 섭취후의 위점막 손상을 억제하기 위한 음료조성물에 관한 것이다.Accordingly, the present invention relates to a beverage composition for inhibiting gastric mucosal injury after alcohol consumption.
더욱 구체적으로, 본 발명은 미강과 탈지대두의 혼합발효액을 함유하는, 알코올에 의한 위점막 손상 억제용 음료조성물에 관한 것이다.More specifically, the present invention relates to a beverage composition for inhibiting gastric mucosal damage by alcohol containing a mixed fermentation liquid of rice bran and defatted soybean.
본 발명의 조성물에서 주성분으로 사용되는 미강과 탈지대두의 혼합발효액은 상기 언급한 특허 제84493 호(공고번호 제95-456호)에 기술된 방법에 의해 미강과 탈지대두를 원료로하여 젖산균과 납두균을 접종하여 발효시켜 제조된 것을 사용한다. 즉, 구체적으로 본 발명의 조성물에서 미강과 탈지대두의 혼합 발효액은 미강에 당화효소를 작용시켜 얻은 당화액에 탈지대두를 혼합하여 121℃에서 30분 동안 멸균시킨 후, 젖산균과 납두균을 접종하여 30내지 40℃, pH 9-9.5에서 50내지 100시간 동안 발효시킨 후, 발효액을 압착여과하여 고형물을 제거하고, 탈색 및 탈취하여 140℃ 에서 4초 동안 살균하여 얻은 발효액이다.The mixed fermentation broth of rice bran and defatted soybean used as a main component in the composition of the present invention is prepared by the method described in the above-mentioned Patent No. 84493 (Publication No. 95-456) using rice bran and defatted soybean as raw materials, Is used for fermentation. Specifically, in the composition of the present invention, the mixed fermentation broth of rice bran and defatted soybean was prepared by mixing saccharification solution obtained by applying saccharogenic enzyme to rice bran, sterilized at 121 ° C for 30 minutes, and then inoculated with lactic acid bacteria and lead The fermentation broth is obtained by filtration of the fermentation broth by filtration, removing the solid matter, decolorizing and deodorizing and sterilizing at 140 ° C for 4 seconds after fermentation at 40 to 40 ° C and pH 9 to 9.5 for 50 to 100 hours.
본 발명의 음료조성물은 목적하는 효과를 얻기 위해서 통상 음주전에, 바람직하게는 알코올을 섭취하기 직전 내지 2시간 전에 음용함으로써 알코올 섭취후에 나타나는 급성 위점막 손상을 억제할 수 있다.The beverage composition of the present invention can inhibit acute gastric mucosal damage appearing after alcohol consumption by drinking usually before drinking, preferably before drinking, before 2 hours before consumption of alcohol.
본 발명의 조성물에서 미강과 탈지대두의 혼합발효액은 일반적으로 성인의음료조성물 총량에 대해 1내지 10%(v/v), 특히는 3내지 7%(v/v) 의 비율로 함유되도록 하는 것이 위점막 손상 억제작용의 관점에서 바람직하다.In the composition of the present invention, the mixed fermentation broth of rice bran and defatted soybean is generally contained in an amount of 1 to 10% (v / v), particularly 3 to 7% (v / v) From the viewpoint of gastric mucosal injury-suppressing action.
본 발명의 조성물에는 또한 미강과 탈지대두의 혼합발효액 이외에 추가로 알코올 섭취후의 제증상을 경감시키는 성분들, 예를들면 혈중 알코올 농도 저하용 약제, 비타민제, 당류, 생약 추출물, 또는 약제학적으로 허용되는 첨가제 등이 포함될 수 있다. 이러한 목적으로 첨가되는 성분들의 구체적인 예로는 과당, 설탕, 구연산, 비타민 B2, 비타민 C, 베타사이클로덱스트린, 녹차 추출물, 영지 추출물 등이 언급될 수 있다. 본 발명은 이하의 실험예에 의해 더욱 구체적으로 설명되나 본 발명이 이들에 의해 어떤 식으로든 제한되는 것은 아니다.The composition of the present invention may further contain, in addition to the mixed fermentation broth of rice bran and defatted soybean, a composition for alleviating symptoms after ingestion of alcohol, for example, a drug for lowering blood alcohol concentration, a vitamin agent, a saccharide, a herbal medicine extract, Additives, and the like. Specific examples of the ingredients added for this purpose include fructose, sugar, citric acid, vitamin B 2 , vitamin C, betacyclodextrin, green tea extract, and ganoderma extract. The present invention will be described more specifically by the following experimental examples, but the present invention is not limited thereto in any way.
실험예 1Experimental Example 1
위점막 손상에 대한 억제효과Inhibitory effect on gastric mucosal injury
본 발명의 조성물의 유효성분인 미강과 탈지대두의 혼합발효액이 알코올 섭취후의 위점막 손상을 억제하는지 여부를 확인하기 위하여 다음과 같은 실험을 수행하였다. 실험동물로는 체중 180g내지 200g의 스프라그 도울리(Sprague Dawley)계 자성 백서를 이용하였다. 실험동물을 실험전 24시간 동안 절대 금식시킨 후, 급식튜브(feeding tube)를 구강을 통해 위내에 삽입하고, 이 튜브를 통해 실험약제를 투여하였다.The following experiment was conducted to confirm whether the mixed fermentation broth of rice bran and defatted soybean, which are effective ingredients of the composition of the present invention, inhibits gastric mucosal damage after alcohol consumption. Sprague Dawley magnetic white paper with a weight of 180 g to 200 g was used as an experimental animal. The experimental animals were fasted for 24 hours before the experiment, and a feeding tube was inserted into the stomach through the oral cavity, and the experimental drug was administered through the tube.
실험약제로는 다음 표1 에 기재된 바와 같은 조성으로 구성된 약제 A 및 B 를 사용하였다.Agents A and B having the composition as shown in the following Table 1 were used as experimental drugs.
상기 각각의 실험약제인 약제 A및 B를 각각 상용량(상기 표 1에 따라 제조된 양)의 0.33배, 1배 및 3배의 농도로 만든 후 각각의 농도당 5㎖/kg의 용량으로 위강내 주입하였으며, 대조군에는 생리식염수를 5㎖/kg의 용량으로 투여하였다. 각 실험군에는 실험동물이 8 마리씩 포함되도록 하였다. 실험동물에게 실험 약제 또는 생리식염수를 투여하고 15분이 경과한 후에 예비실험에서 결정된 양으로 에탄올을 10㎖/kg 의 용량으로 급식튜브를 통해 위강내에 투여하고 1시간이 경과한 다음 에테르 마취하에 복부를 절개하고 위를 적출하여 대만부를 따라 절개하여 생리식염수로 세척한 다음 위점막 병변을 관찰하며 사진촬영을 하였다. 즉시 위점막을 -70℃에 보관하였으며, 이하의 실험에서 병리학적 검사에 사용하였다. 병리학적 검사에 의한 병변부위율의 계산은 계측의 정확도를 기하기 위하여 촬영된 사진을 컴퓨터를 이용한 영상분석 프로그램을 사용하여 크기를 반복 측정하였으며 적출된 위점막 전체 면적에 대한 병변부 면적의 비율로 환산하였다. 측정된 결과는 다음 표 2에 나타내었다.Each of the aforementioned experimental agents, agents A and B, was made to have a concentration of 0.33, 1 and 3 times the standard dose (the amount prepared according to the above Table 1), and then administered at a dose of 5 ml / kg for each concentration And physiological saline was administered to the control group at a dose of 5 ml / kg. Each experimental group contained 8 animals. After 15 minutes of administration of the experimental drug or physiological saline to the experimental animals, ethanol was administered into the stomach through the feeding tube at a dose of 10 ml / kg in an amount determined in the preliminary experiment, and after 1 hour, And the stomach was excised. The stomach was incised along the Taiwanese side, washed with physiological saline, and then examined for gastric mucosal lesions. The gastric mucosa was immediately stored at -70 ° C and used for pathological examination in the following experiments. To calculate the lesion site rate by pathologic examination, the size of the photographed photographs was measured repeatedly using a computerized image analysis program and the ratio of the lesion area to the total area of the gastric mucosa Respectively. The measured results are shown in Table 2 below.
궤양 인덱스Ulcer index
(주) 궤양 인덱스 = 궤양부위의 면적/적출된 위점막의 총면적(Note) ulcer index = area of ulcer area / total area of gastric mucosa removed
P : 유의성, 단 B(X0.33) 대 B(X3) 의 유의성은 P＜0.05P: significance, significance of B (X0.33) to B (X3) was P <0.05
(X 0.33) : 상용량의 0.33 배 용량 투여군.(X 0.33): 0.33 times the dose.
(X 1) : 상용량(표 1 에 기재된 양) 투여군.(X < 1 >): Normal dose (amount shown in Table 1).
(X 3) : 상용량의 3 배 용량 투여군.(X 3): three times the dose of the dose.
상기 표 2에 기재된 결과로 부터 알 수 있는 바와 같이, 에탄올을 공급하기 전에 실험약제를 투여한 군과 생리식염수만을 투여하였던 군간의 위점막 병변의 발생정도를 비교해 보면, 생리식염수를 투여한 군의 경우에는 궤양 인덱스가 0.0602 인데 반하여 상용량의 약제 A 및 B를 투여한 군에서는 각각 0.0079 및 0.0174 로 생리식염수만을 투여한 경우에 비하여 통계적으로 의미있게 위점막 병변의 발생이 억제되었다. 또한 약제 A 및 약제 B 는 모두 상용량의 0.33 배 및 3배로 희석 또는 농축하여 투여한 경우에도 각각 생리식염수를 투여한 대조군에 비하여 유의적으로 위점막 병변의 발생을 억제하였으며, 이들의 작용은 약제의 농도에 따라 비례적으로 증가를 나타내었다. 이러한 결과로 부터 미강과 탈지대두의 혼합발효액을 함유하는 본 발명의 조성물은 에탄올에 의한 위점막 병변의 발생에 탁월한 억제효과가 있음을 알 수 있다.As can be seen from the results shown in the above Table 2, in comparison of the incidence of gastric mucosal lesions between the group administered with the experimental drug and the group administered with only the physiological saline before the ethanol was fed, , The ulcer index was 0.0602, whereas the values of 0.0079 and 0.0174 in the group administered with the medicines A and B, respectively, were statistically significantly lower than those in the group administered only the saline solution. In addition, when both the drug A and the drug B were diluted or concentrated at a ratio of 0.33 times and 3 times the normal dose, they significantly inhibited the development of the gastric mucosal lesion compared with the control group administered with physiological saline, And increased proportionally with concentration. From these results, it can be seen that the composition of the present invention containing a mixed fermentation broth of rice bran and defatted soybean has an excellent inhibitory effect on the occurrence of gastric mucosal lesions caused by ethanol.
본 발명은 위점막 손상 억제용 음료조성물에 관한 것이다. 더욱 구체적으로, 본 발명은 미강과 탈지대두의 혼합발효액을 함유하여 알코올 섭취후에 나타나는 위점막 손상을 억제하는 음료조성물에 관한 것이다.The present invention relates to a beverage composition for inhibiting gastric mucosal injury. More specifically, the present invention relates to a beverage composition containing a mixed fermentation liquid of rice bran and defatted soybean to inhibit gastric mucosal damage after alcohol consumption.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1019960030501A KR100386316B1 (en) | 1996-07-25 | 1996-07-25 | Beverage composition for inhibiting gastric mucosal damage, containing fermented liquid of rice bran and defatted soybean |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1019960030501A KR100386316B1 (en) | 1996-07-25 | 1996-07-25 | Beverage composition for inhibiting gastric mucosal damage, containing fermented liquid of rice bran and defatted soybean |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR980008019A true KR980008019A (en) | 1998-04-30 |
| KR100386316B1 KR100386316B1 (en) | 2003-08-21 |
Family
ID=37417551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019960030501A KR100386316B1 (en) | 1996-07-25 | 1996-07-25 | Beverage composition for inhibiting gastric mucosal damage, containing fermented liquid of rice bran and defatted soybean |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR100386316B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005122798A1 (en) * | 2004-06-22 | 2005-12-29 | Cj Corp. | Functional beverage composition for improving ability of learning, concentration and memory |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105360851B (en) * | 2015-10-14 | 2018-04-10 | 哈尔滨工业大学 | Sorrow is escaped grass seasoning drink and preparation method thereof |
| CN105341244B (en) * | 2015-10-14 | 2019-08-23 | 哈尔滨工业大学 | Serial sorrow is escaped careless tea beverage and preparation method thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH069474B2 (en) * | 1990-03-20 | 1994-02-09 | 有限会社ビセイケン | Method for producing alcohol-fermented fermented product and alcohol-fermented fermented food |
| JP2903950B2 (en) * | 1993-06-22 | 1999-06-14 | 株式会社日立製作所 | Power converter |
| KR950010794A (en) * | 1993-10-14 | 1995-05-15 | 김정순 | Hangover beverage composition |
| JP3447446B2 (en) * | 1994-09-27 | 2003-09-16 | 株式会社エヌ・ディー・シー | Method for producing fermented liquid for adding food or beverage and fermented liquid for adding food or beverage |
-
1996
- 1996-07-25 KR KR1019960030501A patent/KR100386316B1/en not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005122798A1 (en) * | 2004-06-22 | 2005-12-29 | Cj Corp. | Functional beverage composition for improving ability of learning, concentration and memory |
Also Published As
| Publication number | Publication date |
|---|---|
| KR100386316B1 (en) | 2003-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2003055481A1 (en) | Organ fibrosis inhibitors | |
| KR20150007493A (en) | Pharmaceutical composition for preventing or treating prostatic hyperplasia and preparation method thereof | |
| DE3319575A1 (en) | THERAPEUTICALLY EFFECTIVE COMPOSITIONS, FOOD AND BEVERAGES | |
| JPS62153220A (en) | Water-based bile acid agent for internal use | |
| CN107970231A (en) | A kind of composition for treating type-II diabetes | |
| KR980008019A (en) | Beverage composition for inhibiting gastric mucosal injury | |
| KR20040084168A (en) | Use of pinitol or chiro-inositol for preventing or treating liver diseases | |
| KR100500373B1 (en) | Composition for hangover cures | |
| JP3228534B2 (en) | Composition for lowering blood alcohol concentration | |
| EP3247323B1 (en) | Chlorophyll composition | |
| JP2891738B2 (en) | Alcohol absorption inhibitor | |
| DE2015877C3 (en) | Medicines used to treat prostate hypertrophy | |
| JP4610730B2 (en) | Composition for calcium supplementation | |
| TWI235663B (en) | Oral liquid preparations | |
| JPS5920223A (en) | Preventing agent for obesity | |
| JP3936245B2 (en) | Antihypertensive | |
| JP2003342186A (en) | Oral liquid formulation composition for rhinitis | |
| JPS62132822A (en) | Remedy for hepatitis | |
| JP2017036228A (en) | Oral composition | |
| Kaur | A Review on Kidney Stones and Its Treatment By Medicinal Plants | |
| JP3088111B2 (en) | Saponin-containing alcohol absorption inhibitor | |
| JP2013010799A (en) | Oral composition | |
| JP2004168766A (en) | alpha-GLUCOSIDASE INHIBITOR | |
| JP2019214622A (en) | Oral composition | |
| JP5167605B2 (en) | Oral composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20060502 Year of fee payment: 4 |
|
| LAPS | Lapse due to unpaid annual fee |